Taking Ozempic and worried about vision loss? This test can help you understand your risk.
Some research suggests that GLP-1 drugs may raise the risk of a rare eye disease that causes full or partial vision loss.
Read Full Article on MarketWatchAI SUMMARY
# Summary Recent research has raised concerns that GLP-1 receptor agonist drugs—including Ozempic (semaglutide) and similar medications—may increase the risk of retinal complications and vision loss, potentially creating liability exposure for manufacturers like Novo Nordisk and Eli Lilly as the market for these diabetes and weight-loss drugs continues to expand. The development of diagnostic tests to identify patients at higher risk could become an emerging healthcare market opportunity while simultaneously driving increased litigation and regulatory scrutiny of GLP-1 drugs, which have achieved block
MENTIONED STOCKS
More Top Stories News
Morgan Stanley’s Mike Wilson says an S&P 500 correction may be exactly what the market needs
Two stock picks from a money manager who expects small-caps to roar in 2027
Novo Nordisk strikes second licensing deal since frosty capital-markets day
Here’s where TSMC is reportedly eyeing a second U.S. site for a chip-making hub
‘I have a low interest rate’: I’m 80 years old. Should I move out of my house because of dangerous stairs?
Content sourced from MarketWatch. Not financial advice.